Recent Developments
In November 2023, CorMedix Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved DefenCath (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in a limited population of adult kidney failure patients receiving chronic hemodialysis via a central venous catheter (CVC).
In June 2023, Merit Medical Systems, Inc., a global medical device manufacturer, announced that it has completed the purchase of Bluegrass Vascular Technologies, Inc. Surfacer Inside-Out Access Catheter System for a total cash consideration of USD 32.5 million. The Surfacer System is a life-saving device for hemodialysis patients on catheters, as well as patients with other illnesses requiring venous access, who experience central venous occlusions.
In August 2022, Teleflex Incorporated, a leading global provider of medical technologies, announced that it has been granted a contract by Vizient, Inc., the largest member-driven healthcare performance improvement firm in the U.S., to deliver Central Venous Access products. Vizient Inc. offers solutions and services that improve the delivery of high-value care by harmonizing cost, quality, and market performance for more than half of the country\'s acute care providers.
U.S. Central Venous Catheter Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients